Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Gross Margin: 2022-2025

Historic Gross Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to 87.50%.

  • Phathom Pharmaceuticals' Gross Margin rose 190.00% to 87.50% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.25%, marking a year-over-year increase of 371.00%. This contributed to the annual value of 85.57% for FY2024, which is 1006.00% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Gross Margin of 87.50% as of Q3 2025, which was up 0.29% from 87.25% recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Gross Margin ranged from a high of 100.00% in Q1 2022 and a low of 75.51% during Q4 2023.
  • Its 3-year average for Gross Margin is 88.08%, with a median of 87.14% in 2024.
  • Its Gross Margin has fluctuated over the past 5 years, first slumped by 2,449bps in 2023, then spiked by 1,163bps in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Gross Margin (Quarterly) stood at 100.00% in 2022, then tumbled by 2,449bps to 75.51% in 2023, then soared by 1,163bps to 87.14% in 2024, then soared by 190bps to 87.50% in 2025.
  • Its Gross Margin was 87.50% in Q3 2025, compared to 87.25% in Q2 2025 and 86.94% in Q1 2025.